Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 10/20 | 0.61 |
| ▸ | EGLN3 | Q9H6Z9 | 4/20 | 0.61 |
| ▸ | VEGFA | P15692 | 4/20 | 0.61 |
| ▸ | FLT1 | P17948 | 4/20 | 0.61 |
| ▸ | TET3 | O43151 | 1/20 | 0.56 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.56 |
| ▸ | ASPH | Q12797 | 1/20 | 0.56 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.56 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.56 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.56 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.56 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921397 | 0.85 | EGLN1 (0.60) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL4367988 | 0.81 | EGLN1 (0.56) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL1921764 | 0.81 | EGLN1 (0.54) | EGLN1EGLN3VEGFAFLT1 | |
| SCHEMBL1921043 | 0.80 | EGLN1 (0.65) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL1921394 | 0.79 | EGLN1 (0.64) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL19393710 | 0.79 | EGLN1 (0.63) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL25241500 | 0.78 | EGLN1 (0.69) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL30748269 | 0.78 | EGLN1 (0.69) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL30432292 | 0.78 | EGLN1 (0.69) | EGLN1EGLN3VEGFAFLT1TET3 | |
| SCHEMBL4370919 | 0.77 | EGLN1 (0.68) | EGLN1EGLN3VEGFAFLT1TET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | claimed |
| EP-4095127-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2022-11-30 | — | — | EP | disclosed |
| EP-3026044-B1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS INC (US) | 2018-11-07 | — | — | EP | disclosed |
| EP-3357911-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-3323807-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics, Inc. (US) | 2018-05-23 | — | — | EP | disclosed |
| EP-3026044-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2016-06-01 | — | — | EP | disclosed |
| EP-2327696-A1 | Prolyl hydroxylase inhibitors and methods of use | Warner Chilcott Company, LLC (PR) | 2011-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | EGLN1 6/4885EGLN3 2/4885VEGFA 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.